TrialClinical and translational science2024

A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.

Rupert Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.